LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

Search

Akebia Therapeutics Inc

Closed

Sector Healthcare

0.92 -2.13

Overview

Share price change

24h

Current

Min

0.92

Max

0.94

Key metrics

By Trading Economics

Income

15M

614K

Sales

14M

56M

P/E

Sector Avg

26.504

23.904

EPS

-0.08

Profit margin

1.093

Employees

167

EBITDA

14M

11M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+449.45 upside

Dividends

By Dow Jones

Next Earnings

23 sie 2024

Market Stats

By TradingEconomics

Market Cap

10M

322M

Previous open

3.05

Previous close

0.92

News Sentiment

By Acuity

50%

50%

98 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Akebia Therapeutics Inc Chart

Related News

28 mar 2024, 10:30 UTC

Major Market Movers

Akebia Shares Rally Premarket After FDA Approves Vafseo

Peer Comparison

Price change

Akebia Therapeutics Inc Forecast

Price Target

By TipRanks

449.45% upside

12 Months Forecast

Average 5 USD  449.45%

High 6 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forAkebia Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 1.05Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

98 / 369 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.